| Literature DB >> 25030610 |
L Guo1, R Gao1, J Xu1, L Jin1, A P Cotrim2, X Yan1, C Zheng2, C M Goldsmith2, Z Shan1, B Hai1, J Zhou1, C Zhang1, B J Baum2, S Wang3.
Abstract
Patients frequently experience a loss of salivary function following irradiation (IR) for the treatment of an oral cavity and oropharyngeal cancer. Herein, we tested if transfer of fibroblast growth factor-2 (FGF2) cDNA could limit salivary dysfunction after fractionated IR (7.5 or 9 Gy for 5 consecutive days to one parotid gland) in the miniature pig (minipig). Parotid salivary flow rates steadily decreased by 16 weeks post-IR, whereas blood flow in the targeted parotid gland began to decrease ~3 days after beginning IR. By 2 weeks, post-IR salivary blood flow was reduced by 50%, at which point it remained stable for the remainder of the study. The single preadministration of a hybrid serotype 5 adenoviral vector encoding FGF2 (AdLTR2EF1a-FGF2) resulted in the protection of parotid microvascular endothelial cells from IR damage and significantly limited the decline of parotid salivary flow. Our results suggest that a local treatment directed at protecting salivary gland endothelial cells may be beneficial for patients undergoing IR for oral cavity and oropharyngeal cancer.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25030610 DOI: 10.1038/gt.2014.63
Source DB: PubMed Journal: Gene Ther ISSN: 0969-7128 Impact factor: 5.250